Published in Proc Natl Acad Sci U S A on February 15, 1994
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol (1994) 4.21
Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev (2000) 3.70
Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A (2004) 3.57
Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A (1994) 3.56
Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol (2000) 3.26
A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A (1996) 3.25
Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol (1998) 2.71
Hepatitis C virus glycoprotein folding: disulfide bond formation and association with calnexin. J Virol (1996) 2.53
Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol (2002) 2.31
Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep (2003) 2.16
Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. J Virol (1998) 2.09
Cross-genotype immunity to hepatitis C virus. J Virol (2004) 1.92
Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol (2003) 1.89
Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol (2005) 1.87
Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J Exp Med (2004) 1.79
Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein. J Virol (2000) 1.76
Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci U S A (2012) 1.74
Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol (1995) 1.63
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol (2007) 1.61
Hepatitis viruses: changing patterns of human disease. Proc Natl Acad Sci U S A (1994) 1.60
Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol (2005) 1.53
Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A (2004) 1.53
Retracted Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model. Proc Natl Acad Sci U S A (2000) 1.51
Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J Virol (2011) 1.49
Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. J Virol (1998) 1.48
Effect of cell polarization on hepatitis C virus entry. J Virol (2007) 1.41
Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J Virol (1999) 1.40
Progress on new vaccine strategies against chronic viral infections. J Clin Invest (2004) 1.38
Hepatitis C: progress and problems. Clin Microbiol Rev (1994) 1.37
Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines (2011) 1.37
Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis (2010) 1.30
Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology (2010) 1.28
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine (2010) 1.28
Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 1.28
Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (gp70) hypervariable region 1 in viremic hepatitis C virus-infected patients. J Virol (1995) 1.28
Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A (2003) 1.26
Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog (2008) 1.24
Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. J Virol (2001) 1.19
Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J Virol (2003) 1.18
Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol (2001) 1.17
Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol (1997) 1.17
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One (2013) 1.16
Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines (2009) 1.16
Ever closer to a prophylactic vaccine for HCV. Expert Opin Biol Ther (2013) 1.15
Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain. J Virol (2009) 1.13
Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol (2000) 1.13
Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis (2011) 1.10
Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J Virol (2004) 1.09
The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res (2014) 1.07
Genomic and phylogenetic analysis of hepatitis C virus isolates from argentine patients: a six-year retrospective study. J Clin Microbiol (2000) 1.06
Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol (2008) 1.05
DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol (1995) 1.03
Folding of hepatitis C virus E1 glycoprotein in a cell-free system. J Virol (2001) 1.02
Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis. J Clin Microbiol (2005) 0.99
The management of chronic hepatitis C virus infection. Gut (1995) 0.99
Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol (2014) 0.98
Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle. J Virol (2006) 0.98
Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J Virol (1998) 0.97
Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector. J Virol (2002) 0.97
Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. Front Microbiol (2014) 0.96
Clinical relevance of hepatitis C virus genotypes. Gut (1997) 0.95
Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol (2007) 0.95
Production and characterization of monoclonal antibodies specific for a conserved epitope within hepatitis C virus hypervariable region 1. J Virol (2001) 0.94
Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. J Virol (2012) 0.92
Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol (2001) 0.92
Immunogenicity and cross-reactivity of a representative ancestral sequence in hepatitis C virus infection. J Immunol (2012) 0.91
Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses. J Virol (2014) 0.90
Identification of a domain containing B-cell epitopes in hepatitis C virus E2 glycoprotein by using mouse monoclonal antibodies. J Virol (1999) 0.90
Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice. J Virol (2000) 0.89
A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses. World J Gastroenterol (2004) 0.89
Hepatitis C virus antigenic convergence. Sci Rep (2012) 0.89
Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. J Virol (1999) 0.89
Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. J Infect Dis (2011) 0.88
Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J Virol (1997) 0.87
Hepatitis C virus vaccines among people who inject drugs. Clin Infect Dis (2013) 0.87
Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex. J Virol (2014) 0.87
Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups. Dig Dis Sci (1996) 0.87
Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. Curr Opin Virol (2015) 0.86
Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats. Virol J (2009) 0.86
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses (2015) 0.84
Influence of HIV and HCV on T cell antigen presentation and challenges in the development of vaccines. Front Microbiol (2014) 0.83
DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV. World J Gastroenterol (2002) 0.82
Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses. PLoS One (2012) 0.82
Hepatitis C virus: molecular biology and genetic variability. Dig Dis Sci (1996) 0.81
Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments. J Gastroenterol (2007) 0.81
Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections. Front Microbiol (2014) 0.80
Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives. Viruses (2009) 0.80
Hepatitis C virus and vaccine development. Int J Mol Cell Med (2014) 0.80
GB Virus C/Hepatitis G Virus Envelope Glycoprotein E2: Computational Molecular Features and Immunoinformatics Study. Hepat Mon (2013) 0.79
Purification and application of C-terminally truncated hepatitis C virus E1 proteins expressed in Escherichia coli. World J Gastroenterol (2005) 0.79
HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial. J Viral Hepat (2013) 0.79
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 37.89
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 18.79
Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A (1991) 14.05
The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med (1992) 9.10
Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol (1993) 8.47
Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol (1993) 8.07
Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci U S A (1991) 7.15
Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol (1993) 6.36
Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A (1991) 5.51
Lack of protective immunity against reinfection with hepatitis C virus. Science (1992) 4.94
The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med (1992) 4.88
Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA (1990) 3.41
Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome. J Gen Virol (1993) 3.18
The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. Biochem Biophys Res Commun (1993) 2.67
Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J Virol (1993) 2.58
Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells. Virology (1992) 2.58
Immunity in hepatitis C infection. J Infect Dis (1992) 2.28
Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: reevaluation of the role of HCV in liver disease. Proc Natl Acad Sci U S A (1992) 2.18
Non-A, non-B hepatitis-related hepatocellular carcinoma in a chimpanzee. J Med Primatol (1988) 1.29
Etiology and natural history of post-transfusion and enterically-transmitted non-A, non-B hepatitis. Semin Liver Dis (1986) 1.18
Persistence of HCV despite antibodies to both putative envelope glycoproteins. Lancet (1993) 1.17
Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. J Infect Dis (1993) 1.14
Antibodies to hepatitis C virus in Italian blood donors. Lancet (1989) 1.14
Prevalence of hepatitis C virus antibody among Korean adults. J Korean Med Sci (1992) 1.12
Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use. Rev Infect Dis (1992) 1.05
Detection of hepatitis C virus RNA: comparison of one-stage polymerase chain reaction (PCR) with nested-set PCR. J Clin Microbiol (1993) 1.04
Hepatitis C virus infection in blood donors in Egypt. J Egypt Public Health Assoc (1992) 0.99
Transition of antibody to hepatitis C virus from chronic hepatitis to hepatocellular carcinoma. Jpn J Cancer Res (1990) 0.96
Hepatitis C virus in blood samples from volunteer donors. J Clin Microbiol (1993) 0.93
Prevalence of hepatitis C virus antibodies in Sydney blood donors. Med J Aust (1992) 0.90
Vaccinia virus as vector to express ion channel genes. Methods Enzymol (1992) 0.85
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 37.89
Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A (1991) 14.05
Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature (2003) 10.97
Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem (1995) 9.56
Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet (1990) 8.56
Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med (1989) 8.10
Fate of the mammalian cranial neural crest during tooth and mandibular morphogenesis. Development (2000) 8.07
Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science (1995) 7.87
Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology (1991) 7.33
Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5' untranslated region and poly(A) tails at the 3' end. Proc Natl Acad Sci U S A (1991) 7.13
Primary isolation of TRIC organisms in HeLa 229 cells treated with DEAE-dextran. J Infect Dis (1972) 6.85
The p38 signal transduction pathway: activation and function. Cell Signal (2000) 6.18
Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol (1992) 6.09
BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J (1997) 4.51
Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J Biol Chem (1995) 4.36
A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion non-A, non-B hepatitis in Japan. Nucleic Acids Res (1989) 4.29
Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull (1990) 4.16
Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem (1998) 3.80
Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol (1998) 3.77
Multienzyme systems of DNA replication. Science (1974) 3.66
Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem (1996) 3.63
Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet (1989) 3.42
A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A (1996) 3.25
HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol Cell Biol (1999) 3.21
Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome. J Gen Virol (1993) 3.18
Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol (1992) 3.13
Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Mol Cell Biol (1985) 3.09
Regulation of the MEF2 family of transcription factors by p38. Mol Cell Biol (1999) 3.02
Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med (1990) 2.99
Nucleotide sequence of core and envelope genes of the hepatitis C virus genome derived directly from human healthy carriers. Nucleic Acids Res (1990) 2.76
The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. Biochem Biophys Res Commun (1993) 2.67
Fast magnetic resonance diffusion-weighted imaging of acute human stroke. Neurology (1992) 2.63
Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J Virol (1993) 2.58
Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells. Virology (1992) 2.58
Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol (1993) 2.57
At least five related, but distinct, hepatitis C viral genotypes exist. Proc Natl Acad Sci U S A (1992) 2.56
Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol (2000) 2.54
Ten proteins required for conversion of phiX174 single-stranded DNA to duplex form in vitro. Resolution and reconstitution. J Biol Chem (1975) 2.48
Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. J Biol Chem (1997) 2.47
Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol (1995) 2.46
Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha /beta-I kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc Natl Acad Sci U S A (2001) 2.46
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology (2000) 2.45
Hepatitis C antibody and chronic liver disease in haemophilia. Lancet (1990) 2.44
PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J (1998) 2.44
MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther (2008) 2.43
Primary structure and gene organization of human hepatitis A virus. Proc Natl Acad Sci U S A (1985) 2.43
T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology (1993) 2.39
Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment Pharmacol Ther (2013) 2.38
Gastric distention: a mechanism for postprandial gastroesophageal reflux. Gastroenterology (1985) 2.37
Differentiation of TRIC and LGV organisms based on enhancement of infectivity by DEAE-dextran in cell culture. J Infect Dis (1972) 2.36
Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology (2000) 2.34
Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol (2001) 2.34
Primitive deuterostomes from the Chengjiang Lagerstätte (Lower Cambrian, China). Nature (2001) 2.31
Family history of melanoma and Parkinson disease risk. Neurology (2009) 2.25
The protein products of the myc and myb oncogenes and adenovirus E1a are structurally related. Nature (1984) 2.25
Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev (2000) 2.21
Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology (2010) 2.21
The product of the protooncogene c-src is modified during the cellular response to platelet-derived growth factor. Proc Natl Acad Sci U S A (1985) 2.19
Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: reevaluation of the role of HCV in liver disease. Proc Natl Acad Sci U S A (1992) 2.18
Primary structure of BMK1: a new mammalian map kinase. Biochem Biophys Res Commun (1995) 2.15
Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med (2010) 2.12
Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis. Proc Natl Acad Sci U S A (1990) 2.12
Hepatitis C viral cDNA clones isolated from a healthy carrier donor implicated in post-transfusion non-A, non-B hepatitis. Gene (1990) 2.12
Hepatitis C-associated hepatocellular carcinoma. Hepatology (1990) 2.07
Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol (2000) 2.05
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab (2006) 2.05
Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J Biol Chem (1998) 2.05
Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Immunity (1997) 2.04
Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J (2001) 2.03
HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med (1996) 1.99
The primary structure of p38 gamma: a new member of p38 group of MAP kinases. Biochem Biophys Res Commun (1996) 1.99
A mouse model of Chlamydia trachomatis pneumonitis. J Infect Dis (1980) 1.99
Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol (1989) 1.99
Healing of arterial prostheses in man: its incompleteness. Ann Surg (1972) 1.97
Intrafamilial transmission of hepatitis C virus. Lancet (1989) 1.90
Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med (1993) 1.90
Fast selective black blood MR imaging. Radiology (1991) 1.89
Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest. Mol Cell Biol (2000) 1.88
Bronchial stenosis due to anthracofibrosis. Chest (1998) 1.87
Use of a signature nucleotide sequence of hepatitis C virus for detection of viral RNA in human serum and plasma. J Clin Microbiol (1991) 1.87
Ancestral echinoderms from the Chengjiang deposits of China. Nature (2004) 1.85
NIK is a new Ste20-related kinase that binds NCK and MEKK1 and activates the SAPK/JNK cascade via a conserved regulatory domain. EMBO J (1997) 1.84